BMS-1166 NEW
| Price | $68 | $157 | $237 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-05-19 |
Product Details
| Product Name: BMS-1166 | CAS No.: 1818314-88-3 |
| Purity: 99.22% | Supply Ability: 10g |
| Release date: 2025/05/19 |
Product Introduction
Bioactivity
| Name | BMS-1166 |
| Description | BMS-1166 is a potent inhibitor of the PD-1/PD-L1 interaction. |
| Kinase Assay | Purified proteins in 10 mM Tris (pH 8.0) containing 20 mM NaCl, were concentrated to 5 mg/ml, mixed with the inhibitor in 1:3 molar ratio (protein:compound) and clarified by centrifugation at 15 000 × g for 10 min. Supernatant was used for screening using a sitting-drop vapor diffusion method. Diffraction-quality crystals were obtained at room temperature from 0.1 M Tris pH 8.5 containing 0.2 M magnesium chloride and 30% (w/v) PEG 4000 for the hPD-L1/BMS-1001 complex and from 0.01 M Tris pH 8.4 containing 0.28 M sodium chloride and 27% (w/v) PEG 4000 for hPD-L1/BMS-1166 complex. |
| In vitro | BMS-1166 alleviate the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes. Moreover, the compounds were effective in attenuating the inhibitory effect of the cell surface-associated PD-L1. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 125 mg/mL (194.97 mM), Sonication is recommended. |
| Keywords | PD-L1 | PDL1 | PD-1/PD-L1 | PD1/PDL1 | PD-1 | PD1 | interaction | Inhibitor | inhibit | immune | dimerization | checkpoint | cell | BMS-1166 | BMS1166 | BMS 1166 | activation |
| Inhibitors Related | LSD1-IN-24 | PD-1/PD-L1-IN-9 | Sulfamethoxypyridazine | BMS-202 | PD-1-IN-22 | BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride | IMMH 010 maleate | Camrelizumab | LSD1-IN-27 | BMS-1 | Anti-Mouse PD-1 Antibody (RMP1-14) | PD-L1-IN-3 |
| Related Compound Libraries | Apoptosis Compound Library | Bioactive Compound Library | Anti-Breast Cancer Compound Library | Hematonosis Compound Library | Inhibitor Library | Immuno-Oncology Compound Library | PPI Inhibitor Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Cell Cycle Compound Library | Anti-Liver Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/10mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-07-20 | |
| $0.00/1KG |
VIP3Y
|
Henan Aochuang Chemical Co.,Ltd.
|
2022-10-13 | |
| $0.00/10MG |
VIP3Y
|
HangZhou RunYan Pharma Technology Co.,LTD.
|
2024-09-20 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY